Steroid Protocol for eGPA
For severe eGPA (with poor prognostic factors), initiate IV methylprednisolone pulses of 500-1,000 mg daily for 3 consecutive days (maximum 3 grams total), followed immediately by high-dose oral glucocorticoids at 0.75-1 mg/kg/day. 1 For non-severe disease without poor prognostic factors, high-dose oral glucocorticoids alone (0.75-1 mg/kg/day) are sufficient. 1
Disease Severity Stratification
Before initiating steroids, you must determine disease severity using the Five-Factor Score (FFS) and identify poor prognostic factors:
Poor prognostic factors requiring aggressive treatment:
- Cardiac involvement
- Gastrointestinal involvement (mesenteric ischemia)
- Renal insufficiency (creatinine >150 μmol/L)
- Peripheral neuropathy
- Alveolar hemorrhage
- Limb digital ischemia
- Severe eye disease (central retinal artery/vein occlusion, ischemic optic neuropathy, orbital myositis)
Remission Induction Protocols
Severe Disease (FFS ≥1 or any poor prognostic factor)
Steroid regimen:
- IV pulse therapy: Methylprednisolone 500-1,000 mg IV daily × 3 days 1
- Oral continuation: Prednisone 0.75-1 mg/kg/day immediately after IV pulses 1
- Add immunosuppression: Cyclophosphamide (0.6 g/m² IV every 2 weeks × 1 month, then every 4 weeks) OR rituximab (1 gram IV pulses 2 weeks apart) 1
The REOVAS trial demonstrated rituximab is comparable to cyclophosphamide for severe disease, with similar adverse events and steroid exposure. 1
Non-Severe Disease (FFS = 0)
Steroid regimen:
- High-dose oral prednisone 0.75-1 mg/kg/day alone 1
- Consider adding mepolizumab + glucocorticoids for better steroid-sparing effect 1, 2
- Alternative: Add methotrexate, azathioprine, or mycophenolate mofetil to reduce early relapse risk (35% relapse within first year on steroids alone) 1
Steroid Tapering Strategy
Critical principle: Taper glucocorticoids to the minimum effective dose to reduce toxicity, guided by clinical response rather than fixed schedules. 1, 2
Target goals:
- Remission definition: BVAS = 0 and prednisone ≤7.5 mg/day (for severe disease) 1
- For non-severe disease with mepolizumab: Target ≤4 mg/day 1
Tapering considerations:
- Duration should be individualized based on clinical condition, not predetermined schedules 2
- Recent evidence shows accelerated tapering after mepolizumab initiation achieves earlier GC discontinuation without increased organ damage 3
- Median time to GC discontinuation with mepolizumab: 452 days 3
Maintenance Therapy
After achieving remission:
For severe disease:
- Rituximab, mepolizumab, OR traditional DMARDs (methotrexate, azathioprine, mycophenolate) + low-dose glucocorticoids 1
For non-severe disease:
- Glucocorticoids alone OR combined with mepolizumab (preferred for steroid-sparing) 1
Critical Pitfalls to Avoid
Don't treat based on ANCA titers alone - increases in ANCA levels are poor predictors of flares; base decisions on clinical symptoms plus diagnostic studies 2
Don't miss cardiac involvement - obtain echocardiogram at diagnosis as cardiac disease carries poor prognosis 2
Provide PCP prophylaxis - mandatory for all patients receiving cyclophosphamide or rituximab, continue ≥6 months after last rituximab dose 2
Recognize early relapse risk - 35% of non-severe patients relapse within first year on steroids alone, primarily with respiratory symptoms 1
Monitor for steroid toxicity - EGPA patients have particularly high cumulative steroid exposure; aggressive steroid-sparing strategies are essential 1
Evidence Strength Note
The 2023 Nature Reviews Rheumatology guideline 1 provides the most recent comprehensive recommendations (Level 2b evidence, Grade B), superseding the 2021 ACR/Vasculitis Foundation guideline [2-2] which had very low to low evidence quality. Both guidelines converge on the core steroid protocols outlined above, with the 2023 guideline providing more specific dosing details for IV pulse therapy.